These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 38623759)

  • 1. Vascular Ehlers-Danlos Syndrome: A Comprehensive Natural History Study in a Dutch National Cohort of 142 Patients.
    Demirdas S; van den Bersselaar LM; Lechner R; Bos J; Alsters SIM; Baars MJH; Baas AF; Baysal Ö; van der Crabben SN; Dulfer E; Giesbertz NAA; Helderman-van den Enden ATJM; Hilhorst-Hofstee Y; Kempers MJE; Komdeur FL; Loeys B; Majoor-Krakauer D; Ockeloen CW; Overwater E; van Tintelen PJ; Voorendt M; de Waard V; Maugeri A; Brüggenwirth HT; van de Laar IMBH; Houweling AC
    Circ Genom Precis Med; 2024 Jun; 17(3):e003978. PubMed ID: 38623759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multi-institutional experience in the aortic and arterial pathology in individuals with genetically confirmed vascular Ehlers-Danlos syndrome.
    Shalhub S; Byers PH; Hicks KL; Charlton-Ouw K; Zarkowsky D; Coleman DM; Davis FM; Regalado ES; De Caridi G; Weaver KN; Miller EM; Schermerhorn ML; Shean K; Oderich G; Ribeiro M; Nishikawa C; Behrendt CA; Debus ES; von Kodolitsch Y; Powell RJ; Pepin M; Milewicz DM; Lawrence PF; Woo K
    J Vasc Surg; 2019 Nov; 70(5):1543-1554. PubMed ID: 31126764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Splenic artery pathology presentation, operative interventions, and outcomes in 88 patients with vascular Ehlers-Danlos syndrome.
    Shalhub S; Nkansah R; El-Ghazali A; Hillenbrand CJ; Vaidya SS; Schwarze U; Byers PH
    J Vasc Surg; 2023 Aug; 78(2):394-404. PubMed ID: 37068529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multi-institutional experience in vascular Ehlers-Danlos syndrome diagnosis.
    Shalhub S; Byers PH; Hicks KL; Coleman DM; Davis FM; De Caridi G; Weaver KN; Miller EM; Schermerhorn ML; Shean K; Oderich G; Ribeiro M; Nishikawa C; Charlton-Ouw K; Behrendt CA; Debus ES; von Kodolitsch Y; Zarkowsky D; Powell RJ; Pepin M; Milewicz DM; Regalado ES; Lawrence PF; Woo K
    J Vasc Surg; 2020 Jan; 71(1):149-157. PubMed ID: 31353273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular diagnosis in vascular Ehlers-Danlos syndrome predicts pattern of arterial involvement and outcomes.
    Shalhub S; Black JH; Cecchi AC; Xu Z; Griswold BF; Safi HJ; Milewicz DM; McDonnell NB
    J Vasc Surg; 2014 Jul; 60(1):160-9. PubMed ID: 24650746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spontaneous pneumothorax and hemothorax frequently precede the arterial and intestinal complications of vascular Ehlers-Danlos syndrome.
    Shalhub S; Neptune E; Sanchez DE; Dua A; Arellano N; McDonnell NB; Milewicz DM
    Am J Med Genet A; 2019 May; 179(5):797-802. PubMed ID: 30793832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic aspects of the vascular type of Ehlers-Danlos syndrome (vEDS, EDSIV) in Japan.
    Watanabe A; Kosho T; Wada T; Sakai N; Fujimoto M; Fukushima Y; Shimada T
    Circ J; 2007 Feb; 71(2):261-5. PubMed ID: 17251678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vascular Ehlers-Danlos Syndrome With a Novel Missense COL3A1 Mutation Present With Pulmonary Complications and Iliac Arterial Dissection.
    Gu G; Yang H; Cui L; Fu Y; Li F; Zhou Z; Zheng Y
    Vasc Endovascular Surg; 2018 Feb; 52(2):138-142. PubMed ID: 29216800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Audit of Gastrointestinal Manifestations in Patients with Loeys-Dietz Syndrome and Vascular Ehlers-Danlos Syndrome.
    Wang XJ; Babameto M; Babovic-Vuksanovic D; Bowen JM; Camilleri M
    Dig Dis Sci; 2021 Apr; 66(4):1142-1152. PubMed ID: 32306189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation of two iPSC lines from vascular Ehlers-Danlos Syndrome (vEDS) patients carrying a missense mutation in COL3A1 gene.
    Manhas A; Tripathi D; Noishiki C; Wu D; Liu L; Sallam K; Lee JT; Fukaya E; Sayed N
    Stem Cell Res; 2024 Sep; 79():103485. PubMed ID: 38944978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural history of gastrointestinal manifestations in vascular Ehlers-Danlos syndrome: A 17-year retrospective review.
    Frank M; Adham S; Zinzindohoué F; Jeunemaitre X
    J Gastroenterol Hepatol; 2019 May; 34(5):857-863. PubMed ID: 30357907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-derived extracellular matrix demonstrates role of COL3A1 in blood vessel mechanics.
    Doherty EL; Aw WY; Warren EC; Hockenberry M; Whitworth CP; Krohn G; Howell S; Diekman BO; Legant WR; Nia HT; Hickey AJ; Polacheck WJ
    Acta Biomater; 2023 Aug; 166():346-359. PubMed ID: 37187299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atypical COL3A1 variants (glutamic acid to lysine) cause vascular Ehlers-Danlos syndrome with a consistent phenotype of tissue fragility and skin hyperextensibility.
    Ghali N; Baker D; Brady AF; Burrows N; Cervi E; Cilliers D; Frank M; Germain DP; Hulmes DJS; Jacquemont ML; Kannu P; Lefroy H; Legrand A; Pope FM; Robertson L; Vandersteen A; von Klemperer K; Warburton R; Whiteford M; van Dijk FS
    Genet Med; 2019 Sep; 21(9):2081-2091. PubMed ID: 30837697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive genetic screening for vascular Ehlers-Danlos syndrome through an amplification-based next-generation sequencing system.
    Yamaguchi T; Hayashi S; Hayashi D; Matsuyama T; Koitabashi N; Ogiwara K; Noda M; Nakada C; Fujiki S; Furutachi A; Tanabe Y; Yamanaka M; Ishikawa A; Mizukami M; Mizuguchi A; Sugiura K; Sumi M; Yamazawa H; Izawa A; Wada Y; Fujikawa T; Takiguchi Y; Wakui K; Takano K; Nishio SY; Kosho T
    Am J Med Genet A; 2023 Jan; 191(1):37-51. PubMed ID: 36189931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Novel Frameshift COL3A1 Variant in Vascular Ehlers-Danlos Syndrome.
    Olson SL; Murray ML; Skeik N
    Ann Vasc Surg; 2019 Nov; 61():472.e9-472.e13. PubMed ID: 31394236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transforming growth factor-β and inflammation in vascular (type IV) Ehlers-Danlos syndrome.
    Morissette R; Schoenhoff F; Xu Z; Shilane DA; Griswold BF; Chen W; Yang J; Zhu J; Fert-Bober J; Sloper L; Lehman J; Commins N; Van Eyk JE; McDonnell NB
    Circ Cardiovasc Genet; 2014 Feb; 7(1):80-8. PubMed ID: 24399159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is Exon Skipping a Viable Therapeutic Approach for Vascular Ehlers-Danlos Syndrome with Mutations in
    Utama S; Cale JM; Mitrpant C; Fletcher S; Wilton SD; Aung-Htut MT
    Int J Mol Sci; 2024 Aug; 25(16):. PubMed ID: 39201504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of the 2017 criteria for vascular Ehlers-Danlos syndrome in 50 patients ascertained according to the Villefranche nosology.
    Ritelli M; Rovati C; Venturini M; Chiarelli N; Cinquina V; Castori M; Colombi M
    Clin Genet; 2020 Feb; 97(2):287-295. PubMed ID: 31600821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Celiprolol Treatment in Patients with Vascular Ehlers-Danlos Syndrome.
    Baderkhan H; Wanhainen A; Stenborg A; Stattin EL; Björck M
    Eur J Vasc Endovasc Surg; 2021 Feb; 61(2):326-331. PubMed ID: 33223285
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.